ArticlePloS one2016
Multiple Active Compounds from Viscum album L. Synergistically Converge to Promote Apoptosis in Ewing Sarcoma.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05726383 (MISTOSUS), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
MISTOSUS: Iscador® P (Mistletoe) Immunotherapy To Improve Event Free Survival In Patients With Relapsed Resectable Osteosarcoma
Who cites it
20 citing papers in PubMed, 38 citations in OpenAlex.
- MISTOSUS: a phase II trial ofFuture oncology (London, England) · 2026Trial
- Mistletoe lectin inhibits growth of Myc-amplified small-cell lung cancer.Cancer medicine · 2023Article
- In-Vitro Growth Kinetics of Mesenchymal Stem Cells in Cytotoxicity Tests Using Low-Diluted Viscum Album.Homeopathy : the journal of the Faculty of Homeopathy · 2023Article
- Exploration of Flavonoids as Lead Compounds against Ewing Sarcoma through Molecular Docking, Pharmacogenomics Analysis, and Molecular Dynamics Simulations.Molecules (Basel, Switzerland) · 2023Article
- Pan-cancer analysis of the oncogenic role of the core osteosarcoma gene VCAN in human tumors.American journal of translational research · 2023Article
- Anticancer Activity of Mannose-Specific Lectin, BPL2, from Marine Green AlgaMarine drugs · 2022Article
- Biotechnological Potential of Different Organs of Mistletoe (Plants (Basel, Switzerland) · 2022Article
- The Role of Cyclodextrins in the Design and Development of Triterpene-Based Therapeutic Agents.International journal of molecular sciences · 2022Review
- Plants in Anticancer Drug Discovery: From Molecular Mechanism to Chemoprevention.BioMed research international · 2022Review
- Biological activity of mistletoe: in vitro and in vivo studies and mechanisms of action.Archives of pharmacal research · 2020Review
- The Role of Tyrosine Kinases as a Critical Prognostic Parameter and Its Targeted Therapies in Ewing Sarcoma.Frontiers in cell and developmental biology · 2020Review
- Article
- GADD45A and CDKN1A are involved in apoptosis and cell cycle modulatory effects of viscumTT with further inactivation of the STAT3 pathway.Scientific reports · 2018Article
- Plant Lectins Targeting O-Glycans at the Cell Surface as Tools for Cancer Diagnosis, Prognosis and Therapy.International journal of molecular sciences · 2017Review
- Transcriptomic and proteomic insight into the effects of a defined European mistletoe extract in Ewing sarcoma cells reveals cellular stress responses.BMC complementary and alternative medicine · 2017Article
- Article
- Synergistic Antitumour Properties ofJournal of immunology research · 2017Article
- Selective Immune Modulating Activities ofIntegrative cancer therapiesArticle
- Long-Term Survival of a Patient with Recurrent Dedifferentiated High-Grade Liposarcoma of the Retroperitoneum Under Adjuvant Treatment withIntegrative cancer therapiesArticle
- Integrative Oncology Approach in Advanced Myxofibrosarcoma: A Case Report of Prolonged Survival with High-Dose Vitamin C andCase reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ewing sarcoma is the second most common bone cancer in children and adolescents, with poor prognosis and outcome in ~70% of initial diagnoses and 10-15% of relapses. Hydrophobic triterpene acids and hydrophilic lectins and viscotoxins from European mistletoe (Viscum album L.) demonstrate anticancer properties, but have not yet been investigated for Ewing sarcoma. Commercial Viscum album L. extracts are aqueous, excluding the insoluble triterpenes. We recreated a total mistletoe effect by combining an aqueous extract (viscum) and a triterpene extract (TT) solubilized with cyclodextrins. Ewing sarcoma cells were treated with viscum, TT and viscumTT in vitro, ex vivo and in vivo. In vitro and ex vivo treatment of Ewing sarcoma cells with viscum inhibited proliferation and induced apoptosis in a dose-dependent fashion, while viscumTT combination treatment generated a synergistic effect. Apoptosis occurred via intrinsic and extrinsic apoptotic pathways, evidenced by activation of both CASP8 and CASP9. We show that viscumTT treatment shifts the balance of apoptotic regulatory proteins towards apoptosis, mainly via CLSPN, MCL1, BIRC5 and XIAP downregulation. ViscumTT also demonstrated strong antitumor activity in a cell line- and patient-derived mouse model, and may be considered an adjuvant therapy option for pediatric patients with Ewing sarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.